Inhibrx Inc INBX

NAS: INBX | ISIN: US45720L1070   15:59
34,35 USD (+0,99%)
(+0,99%)   15:59

27 maart 2024 · TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX · Persbericht

12 maart 2024 · INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN · Persbericht

28 februari 2024 · Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results · Persbericht

23 januari 2024 · Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B · Persbericht

9 november 2023 · Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights · Persbericht

2 november 2023 · Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma · Persbericht

18 oktober 2023 · Inhibrx Announces Participation in Upcoming Scientific Conferences · Persbericht

19 september 2023 · Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada · Persbericht

29 augustus 2023 · Inhibrx Announces $200 Million Private Placement Financing · Persbericht

7 augustus 2023 · Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights · Persbericht

30 mei 2023 · Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency · Persbericht

8 mei 2023 · Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights · Persbericht

26 april 2023 · Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials · Persbericht

6 maart 2023 · Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results · Persbericht

4 januari 2023 · NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates · Persbericht

18 november 2022 · Inhibrx Announces Participation in Upcoming Investor Conference · Persbericht

16 november 2022 · Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma · Persbericht

7 november 2022 · Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights · Persbericht

20 oktober 2022 · Inhibrx Announces Participation in Upcoming Scientific Conferences · Persbericht

5 oktober 2022 · R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing · Persbericht

Mijn selecties